A two-time breast cancer survivor who was diagnosed with chronic lymphocytic leukemia in 2020 discussed her belief in the power of minimal residual disease testing. Two-time breast cancer survivor Sue ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with ...

MRD-guided therapy for CLL balances treatment cessation risks with cumulative toxicity concerns, offering a promising alternative to continuous or fixed-duration therapies. The VISION/HOVON141 trial ...

Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels. The following article features coverage from the American Society of Hematology 2020 meeting. Click ...

ATLANTA -- Roughly nine of 10 so-called fit patients with chronic lymphocytic leukemia (CLL) achieved undetectable minimal residual disease (MRD) status after treatment with one of two venetoclax ...

For patients with chronic lymphocytic leukemia (CLL), minimal residual disease (MRD) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment, and has ...

Venetoclax and ibrutinib are therapeutic agents for CLL. Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation. The following article features coverage from the American ...

In patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), a once-daily oral regimen of ibrutinib and venetoclax was associated with deep molecular ...

A Media Snippet accompanying this announcement is available by clicking on the image or link below: SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a ...

- New five-year, follow-up analysis from the Phase 3 MURANO trial shows median progression-free survival (PFS) of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in ...

Detectable amounts of minimal residual disease after treatment for CLL does not mean that all hope is lost for survival without disease progression. Patients with chronic lymphocytic leukemia (CLL) ...

SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...